

**ASX Announcement**

**18 September 2024**

## **Results of Extraordinary General Meeting**

**Melbourne, Australia – 18 September 2024:** Pancreatic cancer treatment device company **OncoSil Medical Ltd (ASX: OSL)** (“**OncoSil**” or the “**Company**”) advises that the resolution considered at the Extraordinary General Meeting held today was carried by poll.

In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of the resolution is attached.

**Christian Dal Cin**  
CFO & Company Secretary

**OncoSil Medical Ltd**  
**General Meeting**  
**Wednesday, 18 September 2024**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

| Resolution details   |                    | Instructions given to validly appointed proxies<br>(as at proxy close) |                    |                       |         | Number of votes cast on the poll<br>(where applicable) |                           |                | Resolution<br>Result     | If s250U<br>applies |
|--|--------------------|--|--------------------|-----------------------|---------|--|---------------------------|----------------|--------------------------|---------------------|
| Resolution   | Resolution<br>Type | For  | Against            | Proxy's<br>Discretion | Abstain | For  | Against                   | Abstain*       | Carried /<br>Not Carried |                     |
| 1. Ratification of prior<br>issue of Placement Shares<br>and Placement Options | Ordinary           | 485,060,918<br>96.14%  | 1,780,219<br>0.35% | 17,669,661<br>3.50%   | 156,605 | <b>502,910,579</b><br>99.64%                           | <b>1,800,219</b><br>0.36% | <b>156,605</b> | Carried                  | NA                  |

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.